BioCentury
ARTICLE | Company News

GenVec, Fuso Pharmaceutical Industries Ltd. deal

December 16, 2002 8:00 AM UTC

GNVC and Fuso partnered to develop a targeted cancer therapy based on the tumor necrosis factor alpha gene (TNF-alpha). Under the three-year deal, GNVC will have worldwide rights, excluding Japan, to...